Jump to content

Jeffery W. Kelly: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
COPY from Tafamidis and copyedit, replacing promotional content sourced only to Kelly's papers
 
(33 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{short description|American businessman and chemist (born 1960)}}
{{cleanup-reorganize|date=October 2017}}
{{Use mdy dates|date=March 2024}}
{{Infobox scientist
{{Infobox scientist
| name =
| name =
| native_name =
| native_name =
| native_name_lang =
| native_name_lang =
| image = <!--(filename only, i.e. without "File:" prefix)-->
| image = <!--(filename only, i.e. without "File:" prefix)-->
| image_size =
| image_size =
| caption =
| caption =
| birth_date = {{birth date |1960|08|23}}
| birth_date = {{birth date and age|1960|08|23}}
| birth_place = [[Medina, NY]]
| birth_place = [[Medina, New York]], U.S.
| death_date = <!--{{death date and age |YYYY|MM|DD |YYYY|MM|DD}} (death date then birth date)-->
| death_date = <!--{{death date and age |YYYY|MM|DD |YYYY|MM|DD}} (death date then birth date)-->
| death_place =
| death_place =
| death_cause =
| death_cause =
| citizenship =
| citizenship =
| nationality =
| fields =
| fields =
| workplaces = {{plainlist|
| workplaces = {{plainlist|
Line 25: Line 25:
}}
}}
| known_for =
| known_for =
| awards = [[Breakthrough Prize in Life Sciences]] (2022)<br>[[Wolf Prize]] (2023)
| awards =
| spouse = <!--(or | spouses = )-->
| spouse = <!--(or | spouses = )-->
| children =
| children =
}}
}}


'''Jeffery W. Kelly''' (born August 23, 1960 in [[Medina, New York]]) is an American businessman and chemist who is on the faculty of the [[Scripps Research Institute]] in [[La Jolla, California]].
{{BLP sources|date=December 2010}}


==Biography==
'''Jeffery W. Kelly''' (born August 23, 1960 in [[Medina, New York]]) is the former Dean of Graduate Studies (2000-2008) and Vice President of Academic Affairs (2000-2006) and currently is the Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The [[Scripps Research Institute]] in [[La Jolla, California]].<ref name="bio1">[http://www.scripps.edu/skaggs/kelly/dr_kelly.php?a=l&cid=1 The Kelly Group], Scripps.edu, Retrieved December 10, 2010</ref> His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical<ref>Johnson, S.; Green, N.; Adamanski-Werner, S.; Kelly, J.W. "Native State Kinetic Stabilization as a Strategy to Ameliorate Protein Misfolding Diseases: A focus on the Transthyretin Amyloidoses" Acct. Chem. Res. 2005 38, 911-921.</ref> and biological strategies<ref>Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. “Adapting Proteostasis For Disease Intervention” Science 2008 319, 916-919.</ref> to ameliorate diseases caused by protein misfolding and/or aggregation.
Kelly received his Ph.D. in organic chemistry from the [[University of North Carolina]] at Chapel Hill (1986) and performed post-doctoral research at The [[Rockefeller University]] (1986–89).<ref name="bio1"/>


He is former Dean of Graduate Studies (2000–2008) and Vice President of Academic Affairs (2000–2006) and co-Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The [[Scripps Research Institute]] in [[La Jolla, California]]. His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical and biological strategies to ameliorate diseases caused by protein misfolding and/or aggregation.<ref name="bio1">[http://www.scripps.edu/research/faculty/kelly Faculty biography], Scripps, Retrieved April 2, 2018</ref>
Kelly received his Ph.D. in organic chemistry from the [[University of North Carolina]] at Chapel Hill (1986) and performed post-doctoral research at The [[Rockefeller University]] (1986–89). His research focuses on the chemistry and biology of protein homeostasis or ''[[proteostasis]]''.<ref>Lindquist, S.L.; Kelly, J.W. “Chemical and Biological Approaches for Adapting Proteostasis to Ameliorate Protein Misfolding and Aggregation Diseases–Progress and Prognosis” Cold Spring Harbor Perspect. Biol. doi10.1101 / cshperspect.a004507 2011, 307-340.</ref> Besides studying the structural and energetic basis underlying [[protein folding]], his laboratory also studies the etiology of [[neurodegenerative disease]]s linked to protein aggregation, including [[Alzheimer's]] disease, [[Parkinson's]] Disease, and the light chain, gelsolin and transthyretin-based amyloidoses–publishing over 330 peer-reviewed papers in this area to date (h-index = > 90; ISI Web of Science). He has also provided insight into genetic diseases associated with loss of protein function, such as the [[lysosomal storage diseases]].<ref>Mu, T-W.; Ong, D.S.T.; Wang, Y-J; Balch, W. E.; Yates, J.R.; Segatori, L.; Kelly, J.W. .”Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases” Cell 2008 134, 769-781.</ref><ref>Sawkar, A.R.; Cheng, W-C.; Beutler, E.: Wong, C.–H.: Balch, W.E.: Kelly, J.W. "Chemical Chaperones Increase the Cellular Activity of N370S β-glucosidase: A Therapeutic Strategy for Gaucher Disease " Proc. Natl. Acad. Sci., 2002, 99, 15428-15433.</ref>


Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals with [[Susan Lindquist]] in 2003,<ref name=CEN2010/> Proteostasis Therapeutics, Inc. with [[Andrew Dillin]] and [[Richard Morimoto]] in 2010,<ref>{{cite news|last1=Timmerman|first1=Luke|title=Proteostasis, with San Diego Roots and Boston Home, Seeks Edge in Alzheimer's and Parkinson's|url=https://www.xconomy.com/boston/2010/05/03/proteostasis-with-san-diego-roots-and-boston-home-seeks-edge-in-alzheimers-and-parkinsons/|work=Xconomy|date=3 May 2010}}</ref> and Misfolding Diagnostics<ref>{{cite web|title=Form S-1|url=https://www.sec.gov/Archives/edgar/data/1445283/000119312515412641/d918922ds1.htm|publisher=Proteostasis Therapeutics via SEC Edgar|date=December 23, 2015}}</ref> in 2012.<ref>{{cite news|last1=Preston|first1=Juliet|title=J&J Creates Space at Janssen Labs for Life Sciences Entrepreneurs|url=https://www.xconomy.com/san-diego/2013/02/05/jj-creates-space-at-janssen-labs-for-life-sciences-entrepreneurs/?single_page=true|work=Xconomy|date=5 February 2013}}</ref>
Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals (with [[Susan Lindquist]]), now owned by Pfizer, Proteostasis Therapeutics, Inc. (with [[Andrew Dillin]] and [[Richard Morimoto]]) (a [[NASDAQ]] public company) and Misfolding Diagnostics (with Xin Jiang and Justin Chapman; a private corporation).


His lab began looking for ways to inhibit [[transthyretin]] fibril formation in the 1990s.<ref>{{cite book|last1=Labaudiniere|first1=Richard|editor1-last=Pryde|editor1-first=David C|editor2-last=Palmer|editor2-first=Michael J|title=Orphan Drugs and Rare Diseases.|date=2014|publisher=Royal Society of Chemistry|series=RSC Drug Discovery Series No. 38|isbn=978-1-84973-806-4|chapter=Chapter 9: Discovery and Development of Tafamidis for the Treatment of TTR Familial Amyloid Polyneuropathy}}</ref>{{rp|210}} Tafamidis was eventually discovered by Kelly's team using a [[structure-based drug design]] strategy; the structure was first published in 2003.<ref name=NRDD2010/><ref name=CEN2010/> In 2003 Kelly co-founded FoldRx with [[Susan Lindquist]] of MIT and the Whitehead Institute<ref name=CEN2010>{{cite journal|last1=Borman|first1=Stu|title=Attacking Amyloids|journal=Chemical & Engineering News|date=25 January 2010|volume=88|issue=4|pages=30–32|doi=10.1021/cen-v088n004.p030}}</ref><ref>{{cite journal|last1=Breznitz|first1=Shiri M.|last2=O'Shea|first2=Rory P.|last3=Allen|first3=Thomas J.|title=University Commercialization Strategies in the Development of Regional Bioclusters|journal=Journal of Product Innovation Management|date=March 2008|volume=25|issue=2|pages=129–142|doi=10.1111/j.1540-5885.2008.00290.x}}</ref> and FoldRx [[drug development|developed]] tafamidis up through submitting an application for marketing approval in Europe in early 2010.<ref name=NRDD2010>{{cite journal|last1=Jones|first1=Dan|title=Modifying protein misfolding|journal=Nature Reviews Drug Discovery|date=29 October 2010|volume=9|issue=11|pages=825–827|doi=10.1038/nrd3316}}</ref> FoldRx was acquired by [[Pfizer]] later that year.<ref name=NRDD2010/>
His lab began looking for ways to inhibit [[transthyretin]] fibril formation in the 1990s.<ref>{{cite book|last1=Labaudiniere|first1=Richard|editor1-last=Pryde|editor1-first=David C|editor2-last=Palmer|editor2-first=Michael J|title=Orphan Drugs and Rare Diseases.|date=2014|publisher=Royal Society of Chemistry|series=RSC Drug Discovery Series No. 38|isbn=978-1-84973-806-4|chapter=Chapter 9: Discovery and Development of Tafamidis for the Treatment of TTR Familial Amyloid Polyneuropathy}}</ref>{{rp|210}} [[Tafamidis]] was eventually discovered by Kelly's team using a [[structure-based drug design]] strategy; the structure was first published in 2003.<ref name=NRDD2010/><ref name=CEN2010/> In 2003 Kelly co-founded FoldRx with [[Susan Lindquist]] of MIT and the Whitehead Institute<ref name=CEN2010>{{cite journal|last1=Borman|first1=Stu|title=Attacking Amyloids|journal=Chemical & Engineering News|date=25 January 2010|volume=88|issue=4|pages=30–32|doi=10.1021/cen-v088n004.p030}}</ref><ref>{{cite journal|last1=Breznitz|first1=Shiri M.|last2=O'Shea|first2=Rory P.|last3=Allen|first3=Thomas J.|title=University Commercialization Strategies in the Development of Regional Bioclusters|journal=Journal of Product Innovation Management|date=March 2008|volume=25|issue=2|pages=129–142|doi=10.1111/j.1540-5885.2008.00290.x}}</ref> and FoldRx [[drug development|developed]] tafamidis up through submitting an application for marketing approval in Europe in early 2010.<ref name=NRDD2010>{{cite journal|last1=Jones|first1=Dan|title=Modifying protein misfolding|journal=Nature Reviews Drug Discovery|date=29 October 2010|volume=9|issue=11|pages=825–827|doi=10.1038/nrd3316}}</ref> FoldRx was acquired by [[Pfizer]] later that year.<ref name=NRDD2010/>


==Honors and awards==
The Kelly Laboratory is credited with demonstrating that transthyretin conformational changes alone are sufficient for amyloidogenesis,<ref>Colon, W.; Kelly, J.W. "Partial Denaturation of Transthyretin is Sufficient for Amyloid Fibril Formation In Vitro." Biochemistry, 1992, 31, 8654-8660.</ref> discovering the first example of functional amyloid in mammals,<ref>Fowler, D.M.; Koulov, A.V.; Alory-Jost, C.; Marks, M.S.; Balch, W.E; Kelly, J.W. "Functional Amyloid Formation Within Mammalian Tissue " PLoS Biology 2006, 4, 100-107.</ref> making major contributions toward understanding β-sheet folding, discovering the "enhanced aromatic sequon"–sequences that are more efficiently N-glycosylated by cells and which stabilize the native state of proteins that they are incorporated into as a consequence of aromatic side chain–N-glycan interactions<ref>Culyba, E.K.; Price, J.L.; Hanson, S.R.; Dhar, A,; Wong, C-H.; Gruebele, M.; Powers, E.T.; Kelly, J.W. “Protein Native State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns” Science 2011, 331, 571-575.</ref> and was corresponding author on and contributed some of the key experimental data demonstrating that altering cellular protein homeostasis or [[proteostasis]] capacity has the potential to alleviate protein misfolding and aggregation diseases.<ref>Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. “Adapting Proteostasis For Disease Intervention” Science 2008, 319, 916-919.</ref><ref>Shoulders, M.D.; Ryno, L.M.; Genereux, J.C.; Moresco, J.J.; Tu, P.G. Wu, C.; Yates, J.R.; Su, A.I.; Kelly, J.W.; Wiseman, R.L. “Stress-Independent Activation of XBP1s and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments” Cell Reports 2013 3, 1279-1292.</ref>
1991 - [[Searle Scholar]] Award<ref name="bio1"/>


1999 - Biophysical Society National Lecturer (Award)
Kelly was elected as a fellow of the [[National Academy of Inventors]] (2017), as a Fellow of the [[Royal Society of Chemistry]] (2017), as a member of the [[American Academy of Arts and Sciences]] (2016), delivered the commencement address at SUNY Fredonia (2016),<ref>see Commencement address at: youtu.be/4YA7btif6A8</ref> and has won numerous awards including the [[American Institute of Chemists]] Chemical Pioneer Award, 2017; the [[Gabbay Award|Jacob Heskel Gabbay Award in Biotechnology and Medicine]], 2016; the [[Royal Society of Chemistry]] Jeremy Knowles Award, 2016; the Biopolymers Murray Goodman Memorial Prize, 2012; the American Chemical Society, Ralph F. Hirschmann Award in Peptide Chemistry, 2012; the Protein Society Emil T. Kaiser Award, 2011; the American Peptide Society Rao Makineni Lectureship (Award), 2011; the American Peptide Society Vincent du Vigneaud Award, 2008; the National Institutes of Health Merit Award, 2006; the American Chemical Society Arthur C. Cope Scholar Award, 2001; the SUNY at Fredonia Alumni Distinguished Achievement Award, 2000; the SUNY at Fredonia Chemistry Dept. Alumni Award, 2000; the Protein Society-Dupont Young Investigator Award, 1999; the Biophysical Society National Lecturer (Award), 1999; and the [[Searle Scholar]] Award, 1991.


1999 - Protein Society-Dupont Young Investigator Award
⚫
==References==

⚫
{{reflist}}
2000 - SUNY at Fredonia Alumni Distinguished Achievement Award

2001 - American Chemical Society Arthur C. Cope Scholar Award

2006 - National Institutes of Health Merit Award

2008 - American Peptide Society Vincent du Vigneaud Award

2011 - American Peptide Society Rao Makineni Lectureship (Award)

2011 - Protein Society Emil T. Kaiser Award

2012 - American Chemical Society, Ralph F. Hirschmann Award in Peptide Chemistry

2012 - the Biopolymers [[Murray Goodman Memorial Prize]]

2016 - [[Royal Society of Chemistry]] Jeremy Knowles Award

2016 - [[Gabbay Award|Jacob Heskel Gabbay Award in Biotechnology and Medicine]]

2016 - Commencement address at SUNY Fredonia.<ref>see Commencement address at: youtu.be/4YA7btif6A8</ref>

2016 - Member of the [[American Academy of Arts and Sciences]]

2017 - Chemical Pioneer Award of the [[American Institute of Chemists]]

2017 - Fellow of the [[Royal Society of Chemistry]]

2017 - Fellow of the [[National Academy of Inventors]]

2022 - [[Breakthrough Prize in Life Sciences]]


2023 - [[Wolf Prize in Chemistry]]<ref>[https://wolffund.org.il/home-page/ Wolf Prize in Chemistry 2023]</ref>
== External links ==
* [http://www.scripps.edu/skaggs/kelly/ Kelly Lab page]


==Significant Papers==
==Significant Papers==
Line 71: Line 103:


2008 Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. “Adapting Proteostasis For Disease Intervention” Science 319, 916-919.
2008 Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. “Adapting Proteostasis For Disease Intervention” Science 319, 916-919.

2010 Wiley; died in a car crash


2011 Culyba, E.K.; Price, J.L.; Hanson, S.R.; Dhar, A,; Wong, C-H.; Gruebele, M.; Powers, E.T.; Kelly, J.W. “Protein Native State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns” Science 331, 571-575.
2011 Culyba, E.K.; Price, J.L.; Hanson, S.R.; Dhar, A,; Wong, C-H.; Gruebele, M.; Powers, E.T.; Kelly, J.W. “Protein Native State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns” Science 331, 571-575.
Line 78: Line 112:
2013 Chen, W; Enck, S.; Price, J.L.; Powers, D.L.; Powers, E.T.; Wong, C-H.; Dyson, H.J.; Kelly, J.W. “The Structural and Energetic Basis of Protein-Carbohydrate Interactions” J. Am. Chem. Soc. 135, 9877-9884.
2013 Chen, W; Enck, S.; Price, J.L.; Powers, D.L.; Powers, E.T.; Wong, C-H.; Dyson, H.J.; Kelly, J.W. “The Structural and Energetic Basis of Protein-Carbohydrate Interactions” J. Am. Chem. Soc. 135, 9877-9884.


⚫
==References==
⚫
{{Authority control}}
⚫
{{reflist}}


⚫
{{Authority control}}
{{Wolf Prize in Chemistry}}
{{DEFAULTSORT:Kelly, Jeffery W.}}
{{DEFAULTSORT:Kelly, Jeffery W.}}

⚫
[[Category:Living people]]
⚫
[[Category:American chemists]]
⚫
[[Category:Scripps Research Institute faculty]]
[[Category:1960 births]]
[[Category:1960 births]]
⚫
[[Category:Living people]]
[[Category:21st-century American businesspeople]]
[[Category:21st-century American chemists]]
[[Category:American chemical industry businesspeople]]
[[Category:Businesspeople from New York (state)]]
[[Category:Businesspeople in the pharmaceutical industry]]
⚫
[[Category:American organic chemists]]
[[Category:People from Medina, New York]]
[[Category:People from Medina, New York]]
⚫
[[Category:Scripps Research faculty]]
[[Category:Scientists from New York (state)]]
[[Category:Wolf Prize in Chemistry laureates]]

Latest revision as of 09:41, 7 April 2024

Jeffery W. Kelly
Born (1960-08-23) August 23, 1960 (age 64)
Medina, New York, U.S.
Alma mater
AwardsBreakthrough Prize in Life Sciences (2022)
Wolf Prize (2023)
Scientific career
Institutions

Jeffery W. Kelly (born August 23, 1960 in Medina, New York) is an American businessman and chemist who is on the faculty of the Scripps Research Institute in La Jolla, California.

Biography

[edit]

Kelly received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill (1986) and performed post-doctoral research at The Rockefeller University (1986–89).[1]

He is former Dean of Graduate Studies (2000–2008) and Vice President of Academic Affairs (2000–2006) and co-Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical and biological strategies to ameliorate diseases caused by protein misfolding and/or aggregation.[1]

Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals with Susan Lindquist in 2003,[2] Proteostasis Therapeutics, Inc. with Andrew Dillin and Richard Morimoto in 2010,[3] and Misfolding Diagnostics[4] in 2012.[5]

His lab began looking for ways to inhibit transthyretin fibril formation in the 1990s.[6]: 210  Tafamidis was eventually discovered by Kelly's team using a structure-based drug design strategy; the structure was first published in 2003.[7][2] In 2003 Kelly co-founded FoldRx with Susan Lindquist of MIT and the Whitehead Institute[2][8] and FoldRx developed tafamidis up through submitting an application for marketing approval in Europe in early 2010.[7] FoldRx was acquired by Pfizer later that year.[7]

Honors and awards

[edit]

1991 - Searle Scholar Award[1]

1999 - Biophysical Society National Lecturer (Award)

1999 - Protein Society-Dupont Young Investigator Award

2000 - SUNY at Fredonia Alumni Distinguished Achievement Award

2001 - American Chemical Society Arthur C. Cope Scholar Award

2006 - National Institutes of Health Merit Award

2008 - American Peptide Society Vincent du Vigneaud Award

2011 - American Peptide Society Rao Makineni Lectureship (Award)

2011 - Protein Society Emil T. Kaiser Award

2012 - American Chemical Society, Ralph F. Hirschmann Award in Peptide Chemistry

2012 - the Biopolymers Murray Goodman Memorial Prize

2016 - Royal Society of Chemistry Jeremy Knowles Award

2016 - Jacob Heskel Gabbay Award in Biotechnology and Medicine

2016 - Commencement address at SUNY Fredonia.[9]

2016 - Member of the American Academy of Arts and Sciences

2017 - Chemical Pioneer Award of the American Institute of Chemists

2017 - Fellow of the Royal Society of Chemistry

2017 - Fellow of the National Academy of Inventors

2022 - Breakthrough Prize in Life Sciences

2023 - Wolf Prize in Chemistry[10]

Significant Papers

[edit]

1992 Colon, W.; Kelly, J.W. "Partial Denaturation of Transthyretin is Sufficient for Amyloid Fibril Formation In Vitro." Biochemistry, 31 8654-8660.

2001 Jager, M.; Nguyen, H.; Crane, J.C.; Kelly, J.W.; Gruebele, M. "The Folding Mechanism of a β-Sheet: The WW Domain" J. Mol. Biol., 311, 373-393.

2001 Hammarstrom, P.; Schneider, F.; Kelly, J.W. "Trans-Suppression of Misfolding In An Amyloid Disease" Science 293, 2459-2461.

2002 Sawkar, A.R.; Cheng, W-C.; Beutler, E.: Wong, C.–H.: Balch, W.E.: Kelly, J.W. "Chemical Chaperones Increase the Cellular Activity of N370S β-glucosidase: A Therapeutic Strategy for Gaucher Disease " Proc. Natl. Acad. Sci. 99, 15428-15433.

2003 Hammarstrom, P.; Wiseman, R. L.; Powers, E.T.; Kelly, J.W. "Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics" Science 299, 713-716.

2004 Deechongkit, S.; Nguyen, H.; Dawson, P.E.; Gruebele, M.; Kelly, J.W. “Context Dependent Contributions of Backbone H-Bonding to β-Sheet Folding Energetics” Nature 430, 101-105.

2005 Sekijima, Y., Wiseman, R.L., Matteson, J., Hammarström, P., Miller,S.R., Balch, W.E., Kelly, J.W. “Biological and Chemical Basis for Tissue Selective Amyloid Disease”Cell 121, 73-85.

2006 Fowler, D.M.; Koulov, A.V.; Alory-Jost, C.; Marks, M.S.; Balch, W.E; Kelly, J.W. "Functional Amyloid Formation Within Mammalian Tissue " PLoS Biology 4, 100-107.

2008 Mu, T-W.; Ong, D.S.T.; Wang, Y-J; Balch, W. E.; Yates, J.R.; Segatori, L.; Kelly, J.W. .”Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases” Cell 134, 769-781.

2008 Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. “Adapting Proteostasis For Disease Intervention” Science 319, 916-919.

2010 Wiley; died in a car crash

2011 Culyba, E.K.; Price, J.L.; Hanson, S.R.; Dhar, A,; Wong, C-H.; Gruebele, M.; Powers, E.T.; Kelly, J.W. “Protein Native State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns” Science 331, 571-575.

2012 Bulawa, C.E.; Connelly, S.; DeVit, M.; Wang, L. Weigel, C.;Fleming, J. Packman, J.; Powers, E.T.; Wiseman, R.L.; Foss, T.R.; Wilson, I.A.; Kelly, J.W.; Labaudiniere, R. “Tafamidis, A Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade” Proc. Natl. Acad. Sci. 109, 9629-9634.

2013 Chen, W; Enck, S.; Price, J.L.; Powers, D.L.; Powers, E.T.; Wong, C-H.; Dyson, H.J.; Kelly, J.W. “The Structural and Energetic Basis of Protein-Carbohydrate Interactions” J. Am. Chem. Soc. 135, 9877-9884.

References

[edit]
  1. ^ a b c Faculty biography, Scripps, Retrieved April 2, 2018
  2. ^ a b c Borman, Stu (January 25, 2010). "Attacking Amyloids". Chemical & Engineering News. 88 (4): 30–32. doi:10.1021/cen-v088n004.p030.
  3. ^ Timmerman, Luke (May 3, 2010). "Proteostasis, with San Diego Roots and Boston Home, Seeks Edge in Alzheimer's and Parkinson's". Xconomy.
  4. ^ "Form S-1". Proteostasis Therapeutics via SEC Edgar. December 23, 2015.
  5. ^ Preston, Juliet (February 5, 2013). "J&J Creates Space at Janssen Labs for Life Sciences Entrepreneurs". Xconomy.
  6. ^ Labaudiniere, Richard (2014). "Chapter 9: Discovery and Development of Tafamidis for the Treatment of TTR Familial Amyloid Polyneuropathy". In Pryde, David C; Palmer, Michael J (eds.). Orphan Drugs and Rare Diseases. RSC Drug Discovery Series No. 38. Royal Society of Chemistry. ISBN 978-1-84973-806-4.
  7. ^ a b c Jones, Dan (October 29, 2010). "Modifying protein misfolding". Nature Reviews Drug Discovery. 9 (11): 825–827. doi:10.1038/nrd3316.
  8. ^ Breznitz, Shiri M.; O'Shea, Rory P.; Allen, Thomas J. (March 2008). "University Commercialization Strategies in the Development of Regional Bioclusters". Journal of Product Innovation Management. 25 (2): 129–142. doi:10.1111/j.1540-5885.2008.00290.x.
  9. ^ see Commencement address at: youtu.be/4YA7btif6A8
  10. ^ Wolf Prize in Chemistry 2023
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Jeffery_W._Kelly&oldid=1217694899"